Clear Cell Adenocarcinoma malady

Wikipedia: Clear cell adenocarcinoma is a type of adenocarcinoma.⁴⁴ more...

MalaCards: Clear Cell Adenocarcinoma, also known as water-clear cell adenocarcinoma, is related to ovarian clear cell adenocarcinoma and ovarian cancer. An important gene associated with Clear Cell Adenocarcinoma is HNF1B (HNF1 homeobox B), and among its related pathways are Transcription Receptor-mediated HIF regulation and Colorectal cancer. The compounds threonine and vincristine have been mentioned in the context of this disorder. Affiliated tissues include ovary, prostate and t cells, and related mouse phenotypes are craniofacial and liver/biliary system.

Disease Ontology: An adenocarcinoma that derives from epithelial cells which have clear cytoplasm.⁶

Aliases & Descriptions:

clear cell adenocarcinoma 6 8 water-clear cell adenocarcinoma 6 43 mesonephroma 6 43 water-clear cell adenocarcinoma (morphologic abnormality) 6 clear cell adenocarcinoma nos (morphologic abnormality) 6 clear cell adenocarcinoma (morphologic abnormality) 6 mesonephroma, malignant (morphologic abnormality) 6 mesonephroma nos (morphologic abnormality) 6

mesonephroid clear cell carcinoma 6 adenocarcinoma, clear cell 43 water-clear cell carcinoma 6 adenocarcinoma clear cell 32 wolffian duct neoplasm 6 malignant mesonephroma 6 mesonephric tumor 43

Diseases related to clear cell adenocarcinoma by text searches and GeneDecks gene sharing:

(show top 50)    (show all 496)

id	Related Disease	Score	Top Affiliating Genes
1	ovarian clear cell adenocarcinoma	32.9	PIK3CA, VEGFA, MUC16, MTOR, CDH1, INHBA
2	ovarian cancer	30.3	RB1, BRCA1, CCNE1, PTHLH
3	adenomyosis	30.1	VEGFA, MUC16, LAMC2, CDH1, ESR1, ESR2
4	nephrogenic adenoma	30.1	PAX8, PAX2, AMACR, TP63, KRT7, KLK3
5	nephrogenic adenoma of the urethra	29.9	KLK3, ACPP
6	renal clear cell carcinoma	28.3	VEGFA, BIRC5, MTOR, CDH1, MET, ANXA4
7	endometriosis	25.2	PIK3CA, BRCA1, VEGFA, BIRC5, MUC16, MTOR
8	epithelial ovarian cancer	25.0	PIK3CA, RB1, BRCA1, VEGFA, BIRC5, PAX2
9	rhabdomyosarcoma	24.6	RB1, VEGFA, MUC16, MTOR, CDH1, MET
10	adenocarcinoma	22.7	PIK3CA, SFRP1, SFRP5, RB1, BRCA1, VEGFA
11	adenoma	21.4	PIK3CA, SFRP1, RB1, BRCA1, VEGFA, BIRC5
12	ovarian carcinoma	21.4	PIK3CA, RB1, BRCA1, VEGFA, BIRC5, PAX8
13	hypoxia	20.5	PIK3CA, SFRP1, RB1, BRCA1, VEGFA, BIRC5
14	prostatitis	19.8	PIK3CA, SFRP1, RB1, BRCA1, VEGFA, BIRC5
15	carcinoma	16.0	PIK3CA, SFRP1, SFRP5, RB1, BRCA1, VEGFA
16	catamenial pneumothorax	13.7	MUC16, ESR1, PGR
17	progesterone resistance	13.7	ESR1, ESR2, PGR
18	adenofibroma	13.7	MUC16, PTEN, PGR
19	endometrial carcinoma, somatic	13.7	CDH1, PTEN
20	hemihypertrophy	13.7	PTEN, WT1, AFP
21	gender identity disorder	13.7	ESR1, ESR2, PGR
22	nephrogenic systemic fibrosis	13.7	PIK3CA, SMAD2, SMAD3
23	glassy cell carcinoma of the cervix	13.7	ESR1, ERBB2, PGR
24	primary malignant lymphoma	13.7	PIK3CA, TP53, PTHLH
25	trigonitis	13.7	ANXA4, ESR1, PGR
26	gastric cancer, somatic	13.6	PIK3CA, CDH1, ERBB2
27	apocrine adenosis of breast	13.6	ERBB2, PGR
28	vulvar syringoma	13.6	ESR1, PGR
29	comedo carcinoma	13.6	ESR1, ERBB2
30	progesterone-receptor negative breast cancer	13.6	ESR1, ERBB2, PGR
31	ovarian carcinosarcoma	13.6	VEGFA, ERBB2, PGR
32	lobular neoplasia	13.6	CDH1, ESR1, ESR2
33	microglandular adenosis	13.6	ESR1, ERBB2, PGR
34	inflammatory breast carcinoma	13.6	CDH1, MET, ESR1, ERBB2
35	hydrocele	13.6	VEGFA, ESR1, AFP
36	breast pericanalicular fibroadenoma	13.6	ESR1, ERBB2, HIF1A, PGR
37	germ cell cancer	13.5	ESR2, ERBB2, TP53, AFP
38	lymphoepithelioma-like carcinoma	13.5	CDH1, TP53, ACPP
39	primary pigmented nodular adrenocortical disease	13.5	ESR1, ESR2, PGR
40	ovarian cyst	13.5	VEGFA, MUC16, ESR1, ESR2, AFP
41	intrahepatic cholestasis of pregnancy	13.5	ESR1, ESR2, TP53, HIF1A
42	lichen sclerosus	13.5	ESR1, ESR2, TP53, HIF1A
43	cellular leiomyoma	13.5	ESR1, DES, PGR
44	myoma	13.5	DES, PGR
45	ovarian brenner tumor	13.5	MUC16, WT1, KRT7
46	hemangioma of liver	13.5	VEGFA, DES
47	mucinous cystadenocarcinoma	13.5	MUC16, SMAD4, KRT7
48	familial colorectal cancer	13.5	PIK3CA, CDH1, TP53, SMAD2
49	recurrent respiratory papillomatosis	13.5	ESR1, ERBB2, TP53
50	progesterone-receptor positive breast cancer	13.4	VEGFA, ESR1, ESR2, ERBB2, PGR

Approved drugs:

Drug clinical trials:

MalaCards organs/tissues related to clear cell adenocarcinoma:

²²

MGI Mouse Phenotypes related to clear cell adenocarcinoma:

²⁵ (show all 26)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	craniofacial phenotype	MP:0005382	9.9	SMAD3, GPC3, INHBA, PAX8
2	liver/biliary system phenotype	MP:0005370	9.2	AHR, HIF1A, SMAD3, SMAD2, TP53, ESR2
3	respiratory system phenotype	MP:0005388	9.2	TP63, MB, BRCA1
4	endocrine/exocrine gland phenotype	MP:0005379	8.9	AFP, WT1, TP63, PAX2, PAX8, BRCA1
5	hematopoietic system phenotype	MP:0005397	8.5	AHR, SMAD4, PTHLH, GPC3, CCNE1, MB
6	no phenotypic analysis	MP:0003012	8.4	AHR, HILPDA, SMAD2, TP53, ESR2, ESR1
7	normal phenotype	MP:0002873	8.0	TP63, ESR2, CCNE1, MAP4, INHBA, MTOR
8	vision/eye phenotype	MP:0005391	7.9	PTEN, PTHLH, SMAD2, SMAD3, HIF1A, TP63
9	adipose tissue phenotype	MP:0005375	7.8	ESR2, TP53, PTEN, PTHLH, ESR1, AMACR
10	behavior/neurological phenotype	MP:0005386	7.7	SMAD2, SMAD3, SMAD4, PDPN, ACPP, DES
11	immune system phenotype	MP:0005387	7.6	PTHLH, SMAD2, SMAD4, PDPN, WT1, AHR
12	nervous system phenotype	MP:0003631	7.6	PTEN, PTHLH, SMAD2, SMAD3, SMAD4, HIF1A
13	reproductive system phenotype	MP:0005389	7.2	AFP, NEU4, WT1, SMAD4, SMAD3, SMAD2
14	limbs/digits/tail phenotype	MP:0005371	7.2	SMAD3, PTHLH, TP63, ERBB2, ESR2, ESR1
15	tumorigenesis	MP:0002006	7.1	PTEN, SMAD2, SMAD3, SMAD4, HIF1A, AHR
16	integument phenotype	MP:0010771	7.0	PTHLH, SMAD2, PDPN, ACPP, AHR, PGR
17	renal/urinary system phenotype	MP:0005367	6.9	AHR, MET, INHBA, LAMC2, MTOR, PAX2
18	embryogenesis phenotype	MP:0005380	6.6	PGR, PIK3CA, SFRP1, TP63, ERBB2, GPC3
19	digestive/alimentary phenotype	MP:0005381	6.3	PTHLH, PTEN, TP63, TP53, SMAD2, SMAD3
20	muscle phenotype	MP:0005369	6.2	PGR, STMN1, DES, AHR, HIF1A, MTOR
21	skeleton phenotype	MP:0005390	5.9	ERBB2, TP53, TP63, PTEN, PTHLH, SMAD2
22	mortality/aging	MP:0010768	5.6	AFP, MET, INHBA, CDH1, LAMC2, PAX2
23	growth/size phenotype	MP:0005378	4.7	WT1, PDPN, SMAD4, SMAD3, SMAD2, PTHLH
24	cardiovascular system phenotype	MP:0005385	4.7	SMAD4, SMAD3, SMAD2, PTHLH, PTEN, TP63
25	cellular phenotype	MP:0005384	4.6	TUBB3, ERBB2, ESR2, ESR1, GPC3, CCNE1
26	homeostasis/metabolism phenotype	MP:0005376	3.7	SMAD4, MB, MET, INHBA, CDH1, MTOR

Articles related to clear cell adenocarcinoma:

(show all 48)

id	Title	Authors	Year	Affiliating Genes
1	Wild-type p53 enhances annexin IV gene expression in ovarian clear cell adenocarcinoma. (21348943)	Masuishi Y.... Hirano H.	2011	TP53, ANXA4
2	PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. (21735444)	Yamamoto S.... Matsubara O.	2011	PIK3CA
3	Re-expression of estrogen receptor I^ inhibits the pro liferation and migration of ovarian clear cell adenocarcinoma cells. (21874257)	Zhu J.... Feng Y.	2011	ESR2
4	Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor pr ogression and prognostication of the patient. (21478826)	Yamamoto S.... Matsubara O.	2011	MET
5	Hepatocyte nuclear factor-1I^ expression in clear cell adenocarcinomas of the bladder and urethra: diagnostic utility and implication s for histogenesis. (21496868)	Brimo F.... Illei P.B.	2011	HNF1B
6	Prognostic and predictive values of E-cadherin for pa tients of ovarian clear cell adenocarcinoma. (21119364)	Ho C.M.... Hsieh C.Y.	2010	CDH1
7	Promoter methylation of sFRP5 in patients with ovaria n clear cell adenocarcinoma. (20486992)	Ho C.M.... Chang S.F.	2010	RB1, BRCA1, BIRC5
8	Transcription factor POU6F1 is important for prolifer ation of clear cell adenocarcinoma of the ovary and is a potential new molecula r target. (20134265)	Suzuki N.... Ishizuka B.	2010	POU6F1
9	CA125-producing clear cell adenocarcinoma arising fro m the upper ureter and renal pelvis. (20103490)	Shih C.M.... Pan C.C.	2010	MUC16
10	Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas. (20134266)	Nishimura S.... Aoki D.	2010	HILPDA
11	Expression of podoplanin in epithelial ovarian carcin omas and its potential as a marker for clear cell adenocarcinoma. (20736762)	Oe S.... Udagawa Y.	2010	PDPN
12	Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma. (20060152)	Herawi M.... Epstein J.I.	2010	PAX2, TP63
13	Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. (19121088)	Miyazawa M.... Osamura R.Y.	2009	VEGFA, HIF1A, MTOR
14	Coexistence of a clear cell adenocarcinoma and an ade nosarcoma with a heterologous rhabdomyosarcoma in an endometriotic cyst of the ovary: a case study. (19483627)	Yasuoka H.... Nakamura Y.	2009	DES, MB
15	POU6F1 is the transcription factor that might be invo lved in cell proliferation of clear cell adenocarcinoma of the ovary. (19874398)	Yoshioka N.... Ishizuka B.	2009	POU6F1
16	Clear cell adenocarcinoma arising from adenomyosis. (19620944)	Hirabayashi K.... Osamura R.Y.	2009	MUC16
17	Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. (19228748)	Aoki D.... Kuwano M.	2009	TUBB3, STMN1, MAP4
18	Glypican-3 expression in clear cell adenocarcinoma of the ovary. (19329941)	Maeda D.... Fukayama M.	2009	GPC3
19	PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas. (19007975)	Ho C.M.... Chang S.F.	2009	PTEN
20	Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma. (19020706)	Saga Y.... Mano H.	2008	GPX3
21	Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis? (18670350)	Tong G.X.... O'Toole K.	2008	PAX2, PAX8
22	Clear cell adenocarcinoma arising from a giant cystic adenomyosis: a case report with immunohistochemical analysis of laminin-5 gamma2 chain and p53 overexpression. (18467037)	Ohta Y.... Ota H.	2008	LAMC2
23	Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma. (18081793)	Rauh-Hain J.A.... Penson R.T.	2008	MUC16
24	Histogenesis of clear cell adenocarcinoma in the urinary tract: evidence of urothelial origin. (18381932)	Sung M.T.... Cheng L.	2008	AMACR
25	Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S. (18788852)	Sun K.... Unger P.D.	2008	KRT7, AMACR
26	Ovarian clear cell adenocarcinoma producing alpha-fetoprotein: case report. (17624099)	Cetin A.... Yavuz E.	2007	AFP
27	Sperm protein 17 influences the tissue-specific malignancy of clear cell adenocarcinoma in human epithelial ovarian cancer. (17309563)	Nakazato T.... Minegishi T.	2007	SPA17
28	Differential expression of ABCF2 protein among different histologic types of epithelial ovarian cancer and in clear cell adenocarcinomas of different organs. (16996567)	Nishimura S.... Mok S.C.	2007	ABCF2
29	Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. (17442376)	Yamamoto S.... Matsubara O.	2007	HNF1B
30	Specific expression of hepatocyte nuclear factor-1beta in the ovarian clear cell adenocarcinoma and its application to cytological diagnosis. (17270029)	Higashiguchi A.... Sakamoto M.	2007	HNF1B
31	Persistent and moderate hypercalcemia related to an ovarian clear cell adenocarcinoma: Pre- and postoperative parathyroid hormone related-peptide and 1,25-dihydroxyvitamin D3 levels. (16794368)	Benit A.... Caron P.	2006	PTHLH
32	Expression of NEU3 (plasma membrane-associated sialidase) in clear cell adenocarcinoma of the ovary: its relationship with T factor of pTNM classification. (17476974)	Nomura H.... Aoki D.	2006	NEU3
33	The autocrine effect of activin A on human ovarian clear cell adenocarcinoma cells. (16820918)	Mabuchi Y.... Umesaki N.	2006	SMAD2, SMAD3, SMAD4
34	PTEN expression in clear cell adenocarcinoma of the ovary. (16290000)	Hashiguchi Y.... Mok S.C.	2006	IFI27
35	WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. (16134181)	Kaneuchi M.... Dahiya R.	2005	WT1
36	Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovary. (15557791)	Tsuda H.... Mok S.C.	2004	CCNE1
37	Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma. (15350366)	Tanabe H.... Tanaka T.	2004	ERBB2
38	Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma. (11790460)	Ogawa S.... Nakano H.	2002	VEGFA
39	Clear cell adenocarcinoma of the female urethra showing strong immunostaining for prostate-specific antigen. (11251541)	Kawano K.... Yasuda K.	2001	KLK3
40	Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma. (11342781)	Fujimura M.... Saito S.	2001	PGR, ESR1, ESR2
41	Steroid sulfatase expression in ovarian clear cell adenocarcinoma: immunohistochemical study. (11520136)	Okuda T.... Farina A.	2001	STS
42	Tubulocystic clear cell adenocarcinoma arising within the prostate. (11023108)	Pan C.C.... Epstein J.I.	2000	ACPP
43	Hypercalcemia due to parathyroid hormone-related protein produced by primary ovarian clear cell adenocarcinoma: case report. (10637074)	Tsunematsu R.... Tsukamoto N.	2000	PTHLH
44	Clear cell adenocarcinoma and nephrogenic adenoma of the urethra and urinary bladder: a histopathologic and immunohistochemical comparison. (9865832)	Gilcrease M.Z.... Albores-Saavedra J.	1998	ACPP, KLK3
45	Clear cell adenocarcinoma of the urethra: a clinicopathologic analysis of 19 cases. (8733766)	Oliva E.... Young R.H.	1996	ACPP
46	Clear cell adenocarcinoma of the female urethra showing positive staining with antibodies to prostate-specific antigen and prostatic acid phosphatase. (7536368)	Ebisuno S.... Nagareda T.	1995	ACPP, KLK3
47	A case of clear cell adenocarcinoma of the female urethra (7645457)	Miyai M.... Ebisuno S.	1995	ACPP, KLK3
48	Clear cell adenocarcinoma of the urethra: evidence for origin within paraurethral ducts. (2294240)	Spencer J.R.... Ignatoff J.M.	1990	ACPP, KLK3

Genes related to clear cell adenocarcinoma according to GeneCards:

(show top 50)    (show all 54)

id	Symbol	Description	Score	GeneCards Section Context
1	HNF1B	HNF1 homeobox B	11.0	Publications
2	NEU4	sialidase 4	11.0
3	GPX3	glutathione peroxidase 3 (plasma)	11.0	Publications
4	INHBA	inhibin, beta A	11.0	Publications
5	ANXA4	annexin A4	11.0	Publications
6	STMN1	stathmin 1	11.0	Publications
7	MAP4	microtubule-associated protein 4	11.0	Publications
8	TUBB3	tubulin, beta 3 class III	11.0	Publications
9	STS	steroid sulfatase (microsomal), isozyme S	11.0	Publications
10	MUC16	mucin 16, cell surface associated	11.0	Publications
11	AFP	alpha-fetoprotein	11.0	Publications
12	PTHLH	parathyroid hormone-like hormone	11.0	Publications
13	AHR	aryl hydrocarbon receptor	11.0	Publications
14	WT1	Wilms tumor 1	11.0	Publications
15	SMAD4	SMAD family member 4	11.0	Publications
16	SMAD3	SMAD family member 3	11.0	Publications
17	SMAD2	SMAD family member 2	11.0	Publications
18	PGR	progesterone receptor	11.0	Publications
19	PTEN	phosphatase and tensin homolog	11.0	Publications
20	PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha	11.0	Publications
21	MET	met proto-oncogene (hepatocyte growth factor receptor)	11.0	Publications
22	MTOR	mechanistic target of rapamycin (serine/threonine kinase)	11.0	Publications
23	CDH1	cadherin 1, type 1, E-cadherin (epithelial)	11.0	Publications
24	HIF1A	hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)	11.0	Publications
25	ESR2	estrogen receptor 2 (ER beta)	11.0	Publications
26	ESR1	estrogen receptor 1	11.0	Publications
27	ERBB2	v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)	11.0	Publications
28	VEGFA	vascular endothelial growth factor A	11.0	Publications
29	TP53	tumor protein p53	11.0	Publications
30	HILPDA	hypoxia inducible lipid droplet-associated	11.0	Publications
31	POU6F1	POU class 6 homeobox 1	11.0	Publications
32	SPA17	sperm autoantigenic protein 17	11.0	Publications
33	SFRP5	secreted frizzled-related protein 5	11.0	Publications
34	NEU3	sialidase 3 (membrane sialidase)	11.0	Publications
35	ABCF2	ATP-binding cassette, sub-family F (GCN20), member 2	11.0	Publications
36	AMACR	alpha-methylacyl-CoA racemase	11.0	Publications
37	ACPP	acid phosphatase, prostate	11.0	Publications
38	SLC22A16	solute carrier family 22 (organic cation/carnitine transporter), member 16	11.0	Expressions
39	PAX8	paired box 8	11.0	Publications
40	PAX2	paired box 2	11.0	Publications
41	CCNE1	cyclin E1	11.0	Publications
42	SFRP1	secreted frizzled-related protein 1	11.0	Publications
43	PDPN	podoplanin	11.0	Publications
44	LAMC2	laminin, gamma 2	11.0	Publications
45	KRT7	keratin 7	11.0	Publications
46	IFI27	interferon, alpha-inducible protein 27	11.0	Publications
47	GPC3	glypican 3	11.0	Publications
48	DES	desmin	11.0	Publications
49	KLK3	kallikrein-related peptidase 3	11.0	Publications
50	MB	myoglobin	11.0	Publications

Pathways related to clear cell adenocarcinoma according to GeneDecks:

(show all 44)

id	Pathway	Score	Top Affiliating Genes
1	Transcription Receptor-mediated HIF regulation10	10.8	HIF1A
2	Colorectal cancer20	10.7	SMAD2, SMAD3
3	Development VEGF signaling and activation10	10.6	PIK3CA
4	Development_Role of Activin A in cell differentiation and proliferation41	10.4	SMAD4, SMAD3, SMAD2, INHBA
5	Development Role of Activin A in cell differentiation and proliferation10	10.4	SMAD4, SMAD3, SMAD2, INHBA
6	Signal transduction PTEN pathway10	10.4	PIK3CA, MTOR, PTEN
7	Transcription P53 signaling pathway10	10.3	VEGFA, MAP4, TP53
8	TGF-beta/Smad Signaling3	10.3	SMAD4, SMAD3, SMAD2, PAX2
9	mTOR signaling pathway20	10.3	HIF1A, MTOR, VEGFA, PIK3CA
10	Transcription_Receptor-mediated HIF regulation41	10.3	HIF1A, PTEN, MTOR, VEGFA, PIK3CA
11	Signal transduction_AKT signaling41	10.3	PTEN, TP53, MET, MTOR, PIK3CA
12	Endometrial cancer20	10.2	PIK3CA, CDH1, ERBB2, TP53, PTEN
13	Adherens junction20	10.2	SMAD4, SMAD3, SMAD2, ERBB2, MET, CDH1
14	TGF-beta Signaling Pathways37	10.2	SMAD4, SMAD3, SMAD2, ESR2, ESR1, MTOR
15	Transcription_Ligand-dependent activation of the ESR1/SP pathway41	10.2	HIF1A, ESR1, CCNE1, VEGFA
16	Development Ligand-independent activation of ESR1 and ESR210	10.2	ERBB2, ESR2, ESR1, PIK3CA
17	Transcription Ligand-dependent activation of the ESR1/SP pathway10	10.2	HIF1A, ESR1, CCNE1, VEGFA
18	Development_Ligand-independent activation of ESR1 and ESR241	10.2	ERBB2, ESR2, ESR1, PIK3CA
19	Development TGF-beta receptor signaling10	10.2	ERBB2, SMAD2, SMAD3, SMAD4
20	Renal cell carcinoma20	10.1	HIF1A, MET
21	Development_TGF-beta receptor signaling41	10.0	ERBB2, SMAD2, SMAD3, SMAD4
22	Translation_Non-genomic (rapid) action of Androgen Receptor41	10.0	PTEN, ERBB2, MTOR, PIK3CA
23	Wnt signaling pathway20	10.0	SMAD4, SMAD3, SMAD2, TP53, SFRP5, SFRP1
24	Focal adhesion20	9.9	PTEN, ERBB2, MET, LAMC2, VEGFA, PIK3CA
25	Selected targets of Oct-3/410	9.9	SMAD4, CDH1, BRCA1
26	Transcription_P53 signaling pathway41	9.9	RB1, VEGFA, MAP4, TP53
27	Chronic myeloid leukemia20	9.9	SMAD4, SMAD3, TP53, RB1, PIK3CA
28	Non-small cell lung cancer20	9.9	RB1, ERBB2, TP53, PIK3CA
29	Glioma20	9.8	PTEN, TP53, MTOR, RB1, PIK3CA
30	Development_VEGF signaling and activation41	9.8	ESR1, PIK3CA, BRCA1, VEGFA
31	Bladder cancer20	9.8	TP53, ERBB2, CDH1, VEGFA, RB1
32	Cell cycle Regulation of G1/S transition (part 1)10	9.8	SMAD4, SMAD3, SMAD2, CCNE1, BRCA1
33	Cell cycle_Regulation of G1/S transition (part 1)41	9.8	SMAD4, SMAD3, SMAD2, CCNE1, BRCA1
34	Melanoma20	9.8	PTEN, TP53, MET, CDH1, RB1, PIK3CA
35	Estrogen-mediated S-Phase Entry36	9.8	ESR2, ESR1, CCNE1, RB1
36	MNAR-PELP1 and Estrogen Receptor Interaction36	9.8	ESR2, ESR1, RB1
37	DNA Damage Induced 14-3-3Sigma Signaling36	9.7	BRCA1, CCNE1, TP53
38	p53 Signaling36	9.7	HIF1A, PTEN, TP53, CCNE1, BRCA1
39	Translation Non-genomic (rapid) action of Androgen Receptor10	9.7	PTEN, ERBB2, MTOR, PIK3CA
40	Cell cycle20	9.7	SMAD4, SMAD3, SMAD2, TP53, CCNE1, RB1
41	Small cell lung cancer20	9.5	PTEN, TP53, CCNE1, LAMC2, RB1, PIK3CA
42	Prostate cancer20	9.1	KLK3, PTEN, TP53, ERBB2, CCNE1, MTOR
43	Molecular Mechanisms of Cancer36	8.9	HIF1A, PTEN, TP53, TUBB3, CCNE1, MET
44	Pathways in cancer20	8.0	PIK3CA, HIF1A, SMAD4, SMAD2, PTEN, TP53

Compounds related to clear cell adenocarcinoma according to GeneDecks:

(show top 50)    (show all 217)

id	Compound	Score	Top Affiliating Genes
1	threonine32	10.1	PAX8, AFP, STMN1, PAX2, WT1
2	vincristine32 34 9 9	13.1	PTHLH, AFP, KLK3
3	progestin32	9.9	DES, AHR, ESR2, CDH1, VEGFA
4	ly29400232	9.8	IFI27, CDH1, ERBB2, SMAD2, SMAD3, PIK3CA
5	rapamycin32 42	10.6	RB1, VEGFA, MET, MTOR
6	dihydrotestosterone32 9 18 9	12.1	PTHLH, SMAD2, SMAD3, SMAD4, KLK3, ACPP
7	b 72332	8.8	KRT7, DES, AFP, WT1, PDPN, MUC16
8	geldanamycin32 9 9	10.8	VEGFA, BIRC5, CDH1, MET, ESR1, ERBB2
9	taxane32	8.8	PGR, KLK3, PTEN, TP53, ERBB2, ESR1
10	trastuzumab32 34 9 9	11.7	IFI27, PIK3CA, VEGFA, BIRC5, ESR1, ERBB2
11	crcs32	8.6	TP53, PTEN, SMAD4, HIF1A, MET, CDH1
12	leptomycin b32	8.6	BIRC5, TP53, SMAD2, SMAD3, SMAD4, HIF1A
13	vitamin d32	8.5	AFP, AHR, ACPP, KLK3, WT1, SMAD3
14	hematoxylin32	8.4	CDH1, AMACR, TP63, PTEN, PDPN, KRT7
15	arsenite32 18	9.4	VEGFA, BIRC5, TP53, PTEN, WT1, HIF1A
16	5-aza-2deoxycytidine32	8.3	PGR, KRT7, PTEN, TP53, ESR2, BRCA1
17	carboplatin32 34 9 9	11.3	MUC16, RB1, BRCA1, AFP, HIF1A, KLK3
18	gefitinib32 34 9 9	11.2	PIK3CA, VEGFA, BIRC5, MTOR, CDH1, MET
19	indole-3-carbinol32	8.1	IFI27, BIRC5, ESR1, TP53, PTEN, KLK3
20	mg 13232 42	9.1	BIRC5, VEGFA, AHR, CDH1, IFI27, ESR1
21	etoposide32 42 9 9	11.1	KLK3, TP53, ERBB2, ESR2, CDH1, BIRC5
22	docetaxel32 34 9 9	11.0	BIRC5, VEGFA, BRCA1, MTOR, CDH1, ESR1
23	arginine32	7.8	IFI27, HNF1B, ESR2, ERBB2, TP63, SMAD4
24	pd 98,05932	7.7	SMAD2, SMAD3, SMAD4, HIF1A, STMN1, PTEN
25	agar32	7.7	PIK3CA, RB1, BRCA1, BIRC5, CDH1, MET
26	matrigel32	7.7	RB1, HIF1A, TP63, KRT7, SMAD3, SMAD2
27	5fluorouracil32	7.7	PIK3CA, RB1, BRCA1, VEGFA, BIRC5, MTOR
28	thymidylate32	7.7	CDH1, RB1, BRCA1, VEGFA, BIRC5, TUBB3
29	tamoxifen32 34 9 9	10.6	VEGFA, BIRC5, MTOR, CDH1, IFI27, ESR1
30	estradiol32 9 18 9	10.5	BRCA1, BIRC5, MTOR, ESR1, ESR2, PTEN
31	cycloheximide32	7.5	MET, ESR1, VEGFA, BIRC5, INHBA, ESR2
32	resveratrol32 9 18 9	10.5	BIRC5, VEGFA, BRCA1, RB1, PIK3CA, MTOR
33	adriamycin32	7.3	PGR, RB1, CDH1, BIRC5, AFP, DES
34	alanine32	7.2	ERBB2, BRCA1, BIRC5, CDH1, MET, MB
35	genistein32 9 18 9	10.2	PTEN, MTOR, BIRC5, BRCA1, RB1, PIK3CA
36	dexamethasone32 42 34 9 9	11.0	SMAD2, PTHLH, AFP, ESR2, AMACR, PGR
37	estrogen32	6.9	SMAD3, WT1, KLK3, ACPP, HIF1A, DES
38	retinoic acid32 42 18	8.7	AMACR, HNF1B, ESR1, ESR2, TUBB3, PTHLH
39	paclitaxel32 34 9 9	9.7	CDH1, AFP, PGR, STMN1, HIF1A, KLK3
40	oligonucleotide32	6.5	AMACR, HNF1B, TP53, PTEN, SMAD2, SMAD3
41	thymidine32 18	7.4	SMAD2, PTHLH, TP63, TP53, IFI27, MET
42	cisplatin32 34 9 9	8.9	AFP, STMN1, HIF1A, ACPP, PTHLH, MTOR
43	steroid32	5.5	PIK3CA, RB1, AHR, DES, STS, PGR
44	progesterone32 42 9 18 9	9.1	PIK3CA, RB1, BRCA1, BIRC5, MUC16, DES
45	serine32	4.8	KLK3, HIF1A, AHR, DES, STS, STMN1
46	doxorubicin32 34 9 9	7.7	WT1, KLK3, HIF1A, AFP, PGR, SLC22A16
47	paraffin32	4.2	RB1, BRCA1, VEGFA, BIRC5, MUC16, CDH1
48	tyrosine32	4.1	SFRP1, SMAD2, SMAD3, PDPN, WT1, KRT7
49	testosterone32 9 18 9	6.9	PIK3CA, PTEN, PTHLH, SMAD3, SMAD4, WT1
50	vegf32	3.8	SMAD3, SMAD4, PDPN, WT1, KRT7, KLK3

Cellular components related to clear cell adenocarcinoma according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	SMAD protein complex	GO:071141	10.3	SMAD4, SMAD3, SMAD2
2	activin responsive factor complex	GO:032444	10.3	SMAD2, SMAD4
3	transcription factor complex	GO:005667	9.9	AHR, HIF1A, SMAD4, SMAD3, SMAD2, HNF1B
4	extracellular space	GO:005615	8.7	AFP, HILPDA, PTHLH, GPX3, GPC3, MET
5	nucleoplasm	GO:005654	7.5	RB1, PGR, HIF1A, WT1, SMAD4, SMAD3
6	nucleolus	GO:005730	7.2	WT1, KRT7, HIF1A, AHR, PGR, SMAD4
7	cytoplasm	GO:005737	6.4	SPA17, SMAD2, SMAD3, SMAD4, WT1, KRT7

Biological processes related to clear cell adenocarcinoma according to GeneDecks:

(show all 41)

id	Name	GO ID	Score	Top Affiliating Genes
1	regulation of binding	GO:051098	10.6	SMAD4, SMAD3, SMAD2
2	regulation of transforming growth factor beta2 production	GO:032909	10.6	SMAD3, SMAD4, HIF1A
3	SMAD protein complex assembly	GO:007183	10.6	SMAD2, SMAD3, SMAD4
4	endoderm development	GO:007492	10.5	SMAD4, SMAD3, SMAD2, PTHLH
5	regulation of transforming growth factor beta receptor signaling pathway	GO:017015	10.5	SMAD4, SMAD3, SMAD2
6	positive regulation of epithelial to mesenchymal transition	GO:010718	10.4	SMAD4, SMAD3, SMAD2
7	pronephros development	GO:048793	10.4	HNF1B, PAX2, PAX8
8	metanephric epithelium development	GO:072207	10.3	WT1, PAX2, PAX8
9	positive regulation of focal adhesion assembly	GO:051894	10.3	SMAD3, VEGFA, SFRP1
10	positive regulation of cellular component movement	GO:051272	10.3	VEGFA, PDPN, STMN1
11	positive regulation of metanephric DCT cell differentiation	GO:2000594	10.3	PAX2, PAX8
12	ureteric bud development	GO:001657	10.3	WT1, SMAD3, SMAD2, SFRP1
13	negative regulation of apoptotic process involved in metanephric nephron tubule development	GO:1900218	10.3	PAX2, PAX8
14	negative regulation of apoptotic process involved in metanephric collecting duct development	GO:1900215	10.3	PAX2, PAX8
15	paraxial mesoderm morphogenesis	GO:048340	10.3	SMAD3, SMAD2
16	negative regulation of mesenchymal cell apoptotic process involved in metanephros development	GO:1900212	10.3	PAX2, PAX8
17	digestive tract morphogenesis	GO:048546	10.3	HIF1A, SFRP5, SFRP1
18	negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis	GO:072305	10.2	PAX2, PAX8
19	response to organic cyclic compound	GO:014070	10.2	STS, AHR, GPX3, MET, SFRP1
20	pronephric field specification	GO:039003	10.2	PAX2, PAX8
21	branching involved in ureteric bud morphogenesis	GO:001658	10.2	WT1, SMAD4, PAX2, PAX8
22	transcription initiation from RNA polymerase II promoter	GO:006367	10.1	PGR, SMAD4, SMAD3, SMAD2, ESR2, ESR1
23	liver development	GO:001889	10.1	MET, CCNE1, SMAD3, AFP
24	cellular response to hypoxia	GO:071456	10.1	HIF1A, TP53, MTOR, VEGFA, SFRP1
25	phosphatidylinositol-mediated signaling	GO:048015	10.1	PTEN, ERBB2, MTOR, PIK3CA
26	male gonad development	GO:008584	10.1	WT1, MET, INHBA, SFRP1
27	negative regulation of planar cell polarity pathway involved in axis elongation	GO:2000041	10.1	SFRP1, SFRP5
28	regulation of metanephric nephron tubule epithelial cell differentiation	GO:072307	9.9	PAX2, PAX8
29	positive regulation of transcription from RNA polymerase II promoter in response to hypoxia	GO:061419	9.9	HIF1A, VEGFA
30	negative regulation of sequence-specific DNA binding transcription factor activity	GO:043433	9.9	PTHLH, ESR1, RB1, SFRP5
31	negative regulation of epithelial cell proliferation	GO:050680	9.8	SFRP1, RB1, ESR2, PTEN
32	negative regulation of transcription from RNA polymerase II promoter	GO:000122	9.8	AHR, WT1, SMAD4, SMAD3, SMAD2, TP53
33	heart development	GO:007507	9.8	POU6F1, WT1, PTEN, ERBB2, MB
34	negative regulation of cell proliferation	GO:008285	9.8	WT1, SMAD4, SMAD2, PTHLH, PTEN, TP53
35	negative regulation of apoptotic process	GO:043066	9.7	WT1, SMAD3, PTEN, TP53, HNF1B, PAX2
36	negative regulation of cell growth	GO:030308	9.5	WT1, SMAD4, SMAD3, TP53, ESR2, INHBA
37	signal transduction	GO:007165	9.2	SPA17, PDPN, HIF1A, STMN1, PGR, ERBB2
38	positive regulation of cell proliferation	GO:008284	9.1	STS, HILPDA, PTHLH, PTEN, BIRC5, VEGFA
39	positive regulation of transcription from RNA polymerase II promoter	GO:045944	7.8	TP53, TP63, SMAD2, SMAD3, SMAD4, HIF1A
40	negative regulation of transcription, DNA-dependent	GO:045892	7.5	WT1, SMAD4, SMAD2, TP63, TP53, PAX2
41	positive regulation of transcription, DNA-dependent	GO:045893	7.4	SFRP1, HIF1A, WT1, SMAD4, SMAD3, SMAD2

Molecular functions related to clear cell adenocarcinoma according to GeneDecks:

(show all 15)

id	Name	GO ID	Score	Top Affiliating Genes
1	core promoter proximal region sequence-specific DNA binding	GO:000987	10.2	PAX2, SMAD3, SMAD4
2	protein binding transcription factor activity	GO:000988	10.2	SMAD3, SMAD4, HIF1A
3	R-SMAD binding	GO:070412	10.1	SMAD4, SMAD3, SMAD2
4	beta-catenin binding	GO:008013	9.7	CDH1, MET, ESR1, SMAD3
5	sequence-specific DNA binding	GO:043565	9.6	POU6F1, AHR, HIF1A, WT1, SMAD4, SMAD3
6	RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive	GO:001077	9.5	HIF1A, WT1, TP63, TP53
7	transcription factor binding	GO:008134	9.5	AHR, HIF1A, SMAD3, SMAD2, TP53, GPX3
8	tubulin binding	GO:015631	9.2	STMN1, MAP4, BIRC5, BRCA1
9	ubiquitin protein ligase binding	GO:031625	9.1	HIF1A, SMAD3, SMAD2, TP53, BRCA1, RB1
10	protein heterodimerization activity	GO:046982	9.0	AHR, HIF1A, TP53, ERBB2, HNF1B, MET
11	sequence-specific DNA binding transcription factor activity	GO:003700	8.6	SMAD4, WT1, HIF1A, AHR, POU6F1, PGR
12	enzyme binding	GO:019899	8.6	PGR, HIF1A, PTEN, TP53, ESR2, ESR1
13	transcription regulatory region DNA binding	GO:044212	8.5	BRCA1, AHR, HIF1A, WT1, SMAD4, SMAD3
14	identical protein binding	GO:042802	8.4	SMAD4, TP63, TP53, ERBB2, ESR1, INHBA
15	protein binding	GO:005515	3.8	SMAD3, SMAD2, PTEN, TP63, TP53, ERBB2